Epoch Investment Partners Inc. Purchases New Stake in Kenvue Inc. (NYSE:KVUE)

Epoch Investment Partners Inc. purchased a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 3,134,243 shares of the company's stock, valued at approximately $66,916,000. Epoch Investment Partners Inc. owned about 0.16% of Kenvue at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Grove Bank & Trust grew its position in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after buying an additional 947 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in Kenvue during the fourth quarter worth about $29,000. SRS Capital Advisors Inc. grew its stake in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after buying an additional 571 shares in the last quarter. Fortitude Family Office LLC increased its holdings in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after buying an additional 777 shares during the period. Finally, Versant Capital Management Inc raised its position in shares of Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after buying an additional 1,441 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Down 0.9 %

Shares of Kenvue stock traded down $0.20 on Thursday, hitting $22.74. 15,417,569 shares of the company's stock traded hands, compared to its average volume of 15,846,232. The company has a fifty day moving average of $22.99 and a two-hundred day moving average of $22.42. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a market capitalization of $43.63 billion, a price-to-earnings ratio of 42.91, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.61%. Kenvue's dividend payout ratio is presently 154.72%.

Wall Street Analyst Weigh In

Several brokerages have commented on KVUE. Piper Sandler boosted their target price on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. Royal Bank of Canada restated a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Citigroup lifted their price target on Kenvue from $21.00 to $22.00 and gave the company a "neutral" rating in a research note on Monday, April 14th. UBS Group lowered their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Friday, February 7th. Finally, Evercore ISI started coverage on shares of Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price on the stock. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.